Because reduced glucose disposal in skeletal muscle largely accounts for the glucose intolerance in diabetic patients [2,23], DARP could be a novel pharmacotherapeutic target for the treatment of diabetes mellitus. Here, ANKRD23 is linked to diabetes mellitus.